{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:51:30Z","timestamp":1773661890233,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ahj.2016.01.019","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T14:09:33Z","timestamp":1455890973000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)"],"prefix":"10.1016","volume":"176","clinical-trial-number":[{"clinical-trial-number":"nct01764633","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01813422","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rishi","family":"Puri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helina","family":"Kassahun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Borgman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ahj.2016.01.019_bb0005","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archinte.1981.00340090024008","article-title":"Lipoproteins, cardiovascular disease, and death. The Framingham Study","volume":"141","author":"Gordon","year":"1981","journal-title":"Arch Intern Med"},{"issue":"24","key":"10.1016\/j.ahj.2016.01.019_bb0010","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1161\/01.CIR.97.24.2433","article-title":"Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization","volume":"97","author":"Aikawa","year":"1998","journal-title":"Circulation"},{"issue":"9841","key":"10.1016\/j.ahj.2016.01.019_bb0015","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ahj.2016.01.019_bb0020","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"8934","key":"10.1016\/j.ahj.2016.01.019_bb0025","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ahj.2016.01.019_bb0030","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"issue":"9326","key":"10.1016\/j.ahj.2016.01.019_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ahj.2016.01.019_bb0040","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ahj.2016.01.019_bb0045","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ahj.2016.01.019_bb0050","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ahj.2016.01.019_bb0055","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ahj.2016.01.019_bb0060","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"9753","key":"10.1016\/j.ahj.2016.01.019_bb0065","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"25 Pt B","key":"10.1016\/j.ahj.2016.01.019_bb0070","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2016.01.019_bb0075","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.ahj.2016.01.019_bb0080","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ahj.2016.01.019_bb0085","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ahj.2016.01.019_bb0090","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2016.01.019_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance\u2014an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.019_bb0100","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/ATVBAHA.114.304477","article-title":"Atheroma progression in hyporesponders to statin therapy","volume":"35","author":"Kataoka","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"25","key":"10.1016\/j.ahj.2016.01.019_bb0105","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"6A","key":"10.1016\/j.ahj.2016.01.019_bb0110","doi-asserted-by":"crossref","first-page":"5M","DOI":"10.1016\/S0002-9149(98)00591-8","article-title":"Clinical trial endpoints: angiograms, events, and plaque instability","volume":"82","author":"Ballantyne","year":"1998","journal-title":"Am J Cardiol"},{"issue":"19","key":"10.1016\/j.ahj.2016.01.019_bb0115","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIRCULATIONAHA.108.773747","article-title":"Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound\u2013derived coronary atheroma burden","volume":"117","author":"Ballantyne","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2016.01.019_bb0120","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/01.CIR.96.5.1432","article-title":"Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study","volume":"96","author":"Bots","year":"1997","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.019_bb0125","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-128-4-199802150-00002","article-title":"The role of carotid arterial intima-media thickness in predicting clinical coronary events","volume":"128","author":"Hodis","year":"1998","journal-title":"Ann Intern Med"},{"issue":"9256","key":"10.1016\/j.ahj.2016.01.019_bb0130","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ahj.2016.01.019_bb0135","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","article-title":"ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness","volume":"106","author":"Taylor","year":"2002","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ahj.2016.01.019_bb0140","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ahj.2016.01.019_bb0145","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.ijcard.2013.03.024","article-title":"Exploring coronary atherosclerosis with intravascular imaging","volume":"168","author":"Puri","year":"2013","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2016.01.019_bb0150","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ehjci\/jet251","article-title":"Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN","volume":"15","author":"Puri","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"13","key":"10.1016\/j.ahj.2016.01.019_bb0155","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.01.036","article-title":"Impact of statins on serial coronary calcification during atheroma progression and regression","volume":"65","author":"Puri","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.ahj.2016.01.019_bb0160","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","article-title":"Intravascular ultrasound\u2013derived measures of coronary atherosclerotic plaque burden and clinical outcome","volume":"55","author":"Nicholls","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2016.01.019_bb0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcin.2012.09.006","article-title":"Left main coronary atherosclerosis progression, constrictive remodeling, and clinical events","volume":"6","author":"Puri","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"15","key":"10.1016\/j.ahj.2016.01.019_bb0170","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ahj.2016.01.019_bb0175","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ahj.2016.01.019_bb0180","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"9493","key":"10.1016\/j.ahj.2016.01.019_bb0185","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ahj.2016.01.019_bb0190","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ahj.2016.01.019_bb0195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.ahj.2016.01.019_bb0200","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ahj.2016.01.019_bb0205","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2016.01.019_bb0210","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","article-title":"Rosuvastatin, proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial","volume":"58","author":"Awan","year":"2012","journal-title":"Clin Chem"},{"issue":"15","key":"10.1016\/j.ahj.2016.01.019_bb0215","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.ahj.2016.01.019_bb0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr Atheroscler Rep"},{"issue":"20","key":"10.1016\/j.ahj.2016.01.019_bb0225","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"issue":"9858","key":"10.1016\/j.ahj.2016.01.019_bb0230","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ahj.2016.01.019_bb0235","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"issue":"33","key":"10.1016\/j.ahj.2016.01.019_bb0240","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ahj.2016.01.019_bb0245","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","article-title":"Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk\u2014primary results from the phase 2 YUKAWA study","volume":"78","author":"Hirayama","year":"2014","journal-title":"Circ J"},{"issue":"9858","key":"10.1016\/j.ahj.2016.01.019_bb0250","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ahj.2016.01.019_bb0255","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2016.01.019_bb0260","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.ahj.2016.01.019_bb0265","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"issue":"9965","key":"10.1016\/j.ahj.2016.01.019_bb0270","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ahj.2016.01.019_bb0275","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ahj.2016.01.019_bb0280","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ahj.2016.01.019_bb0285","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa054699","article-title":"Effect of ACAT inhibition on the progression of coronary atherosclerosis","volume":"354","author":"Nissen","year":"2006","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ahj.2016.01.019_bb0290","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ahj.2016.01.019_bb0295","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2013.277169","article-title":"Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial","volume":"310","author":"Nicholls","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ahj.2016.01.019_bb0300","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1185\/03007995.2011.570746","article-title":"Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN)","volume":"27","author":"Nicholls","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"14","key":"10.1016\/j.ahj.2016.01.019_bb0305","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2016.01.019_bb0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjcard.2014.09.041","article-title":"Gender disparities in evidence-based statin therapy in patients with cardiovascular disease","volume":"115","author":"Virani","year":"2015","journal-title":"Am J Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031600051X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031600051X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:57:12Z","timestamp":1757570232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031600051X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":62,"alternative-id":["S000287031600051X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2016.01.019","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2016.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}